Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 0.45 Normal Saline Clear all

Conditions: Cerebral Edema, Diabetic Ketoacidosis
Interventions: 0.45% saline replacement fluid, 0.9% saline replacement fluid, 0.45% saline intravenous fluid, 0.9% saline Intravenous fluid; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: Up to 17 Years
Enrollment: 1,389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 13
States / cities: Sacramento, California • Aurora, Colorado • Wilmington, Delaware + 10 more

Conditions: PD Effects of GS-0976 (NDI-010976) on Fractional DNL
Interventions: GS-0976, Placebo, 1-13C acetate, Fructose solution; Drug · Other
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism, Pulmonary Embolism With Pulmonary Infarction, Pulmonary Embolism Subacute Massive, Right Ventricular Dysfunction, Right Ventricular Failure
Interventions: Alteplase, Unfractionated heparin, Placebo, Apixaban; Drug
Lead sponsor: Victor Tapson, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Osteoarthritis, Knee
Interventions: XT-150, Placebo; Biological · Drug
Lead sponsor: Xalud Therapeutics, Inc.; Industry
Eligibility: 45 Years to 85 Years
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: La Mesa, California • Napa, California • Santa Monica, California + 1 more

Conditions: Leukemia, Lymphoma, Neuroblastoma, Immunodeficiencies, Anemia
Interventions: Alemtuzumab, Total Body Irradiation, Melphalan, Busulfan, Phenytoin, Fludarabine, Cyclophosphamide, Horse Antithymocyte Globulin, Rabbit Antithymocyte Globulin, Thiotepa; Drug · Radiation
Lead sponsor: Columbia University; Other
Eligibility: Up to 30 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid Use Disorder
Interventions: Buprenorphine, buprenorphine and naloxone, hydromorphone, placebo; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Non Cystic Fibrosis Bronchiectasis
Interventions: CMS, Placebo; Drug · Other
Lead sponsor: Zambon SpA; Industry
Eligibility: 18 Years and older
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 27
States / cities: Newport Beach, California • Palm Springs, California • Reseda, California + 22 more

Conditions: Phelan-McDermid Syndrome, Autism Spectrum Disorder (ASD)
Interventions: Growth Hormone, Saline; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 2 Years to 12 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Bacterial Infections
Interventions: TP-271, Placebo; Drug
Lead sponsor: Tetraphase Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pneumonia
Interventions: TP-271; Drug
Lead sponsor: Tetraphase Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Atrial Fibrillation, Alcohol
Interventions: Ethanol, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years to 81 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Myeloma
Interventions: High-Dose Melphalan HCL for Injection (Propylene Glycol-Free), Autologous Transplantation; Drug · Other
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: Up to 70 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 6
States / cities: Chicago, Illinois • Fairway, Kansas • Worcester, Massachusetts + 3 more

Conditions: Multiple Myeloma
Interventions: Bortezomib 1 mg/m2, Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Melphalan; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 76 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Post Abdominal Surgery Pain
Interventions: CR845 IV 1 mcg/kg, CR845 IV 0.5 mcg/kg, Placebo IV; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 23
States / cities: Sheffield, Alabama • New Haven, Connecticut • Bradenton, Florida + 20 more

Conditions: Skin Cancer Face, Skin Cancer Scalp
Interventions: Nerve Block, Placebo Nerve Block; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dysphagia, GERD, Abdominal Pain
Interventions: Lidocaine, Placebo; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Snakebite, Envenoming, Snake
Interventions: Varespladib intravenous form, varespladib-methyl- oral form, Placebo intravenous form, Placebo - oral form; Drug
Lead sponsor: Ophirex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Phoenix, Arizona • Tucson, Arizona • Palm Springs, California + 7 more

Conditions: Atrial Fibrillation
Interventions: Intravenous caffeine, Masked Placebo; Other
Lead sponsor: Kansas City Heart Rhythm Research Foundation; Other
Eligibility: 21 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Loma Linda, California • Overland Park, Kansas • Independence, Missouri + 2 more

Conditions: Multiple Myeloma
Interventions: Cyclophosphamide, Etoposide, Melphalan, Carmustine, Filgrastim; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
Interventions: anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Up to 60 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Diabetic Ketoacidosis
Interventions: intravenous fluid treatment; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 8 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Hyponatremia
Interventions: 0.9 Normal Saline, 0.45 Normal Saline; Other
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 6 Months to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis

Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism

Efficacy and Safety of XT-150 in Osteoarthritis of the Knee

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder

Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.

A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism

A Phase 1 Safety and PK Study of IV TP-271

A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271

The HOLIDAY (HOw ALcohol InDuces Atrial TachYarrhythmias) Study

Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery

Comparing Numbing Techniques in Mohs Micrographic Surgery

Does Use of Topical Lidocaine in EGD Reduce Amount of IV Midazolam and Fentanyl Required and Shorten Recovery Time

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)

Impact of Intravenous Caffeine on Atrial Electrical Properties and Potential Arrythmia Induction

High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Cerebral Edema in Pediatric Diabetic Ketoacidosis

Reexamining Hypotonic Intravenous Fluid Use